Biden says he’ll be ‘President of all Americans’

first_img– Advertisement – xAmerica, I’m honored that you have chosen me to lead our great country.The work ahead of us will be hard, but I promise you this: I will be a President for all Americans — whether you voted for me or not.I will keep the faith that you have placed in me. pic.twitter.com/moA9qhmjn8— Joe Biden (@JoeBiden) November 7, 2020Perhaps, the din of cheers from his own campaign team make it difficult for Biden to hear the rest of us breaking out the Champagne, the weed, and the confetti, and breathing deep sighs of relief after five days of jaw-clenching and teeth-grinding as the vote count continued and four years of the same as the squatter in the White House took us down, down, down. – Advertisement – Democratic Presidential candidate Joe Biden speaks as US Senator and Vice-Presidential candidate, Kamala Harris, looks on at the Chase Center in Wilmington, Delaware on November 4, 2020. - President Donald Trump and Democratic challenger Joe Biden are squaring off for what could be a legal battle for the White House, running neck-and-neck in the electoral vote count, and several battleground states still in play on November 4. (Photo by JIM WATSON / AFP) (Photo by JIM WATSON/AFP via Getty Images)center_img The truly hard work comes next. But for now, we celebrate together with all the people who worked so hard to make this happen, unifying despite differences to oust the pathetic vulgar extremist who has been misleading the nation in just about every way imaginable. last_img read more

AstraZeneca bets up to $6 billion on new Daiichi cancer drug

first_imgAstraZeneca has been bolstering its portfolio of cancer therapies, particularly ADCs, a major area of focus for the company as it also ploughs on with its coronavirus vaccine candidate.”We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2,” AstraZeneca Chief Executive Pascal Soriot said, referring to a protein found on some cancer cell surfaces.JP Morgan analysts said the drug could bring $1 billion or more in annual sales, adding that since AstraZeneca’s upfront commitments are spread over three years, it could still keep previous dividend cover commitments.DS-1062, which targets the TROP2 protein, belongs to the ADC category of drugs, which link powerful cell toxins to antibodies that cling to cancer cells and spare healthy cells that are damaged during conventional chemotherapy treatments. Britain’s AstraZeneca will pay up to $6 billion to Japan’s Daiichi Sankyo under the drugmakers’ second multi-billion dollar oncology collaboration to develop and market a niche type of targeted cancer treatment.London-listed AstraZeneca said on Monday it would pay $1 billion upfront to Daiichi in staggered payments for an experimental drug called DS-1062, which belongs to a promising class of therapies called antibody drug conjugates (ADC).Further payments would depend on regulatory and sales milestones being achieved. The deal will not affect its 2020 earnings forecast, the British company said. An anti-TROP2 ADC called Trodelvy developed by Immunomedics won U.S. regulatory approval in April to treat an aggressive type of breast cancer, while Chinese firms Kelun Group and Bio-Thera Solutions are also working on TROP2-based biotech drugs.In a further boost to AstraZeneca’s oncology unit, two of its on-market therapies, one for lung cancer and another for blood cancer, won regulatory endorsements for expanded use in Europe.The company and Daiichi had signed a near $7 billion deal in 2019 for an ADC targeting the HER2 protein. The drug is now sold as Enhertu.The drugmakers have also been in talks over supply of the British company’s coronavirus vaccine in Japan.AstraZeneca shares were roughly unchanged at 8,644 pence by 0917 GMT.center_img Topics :last_img read more

Class of 2017 fullback Connor Koch commits to Syracuse as preferred walk-on

first_img Published on May 27, 2016 at 12:15 am Contact Sam: [email protected] | @Sam4TR Class of 2017 fullback Connor Koch committed to Syracuse as a preferred walk-on, he announced via Twitter on Thursday night. Go Orange! ? pic.twitter.com/4kFakYgRmz— Connor Koch (@connorkoch_) May 26, 2016 Facebook Twitter Google+center_img Koch is not ranked by any major recruiting sites. The 6-foot-3, 248-pound Koch runs the 40-yard dash in 4.86 seconds, per his Hudl.com profile. He played fullback and inside linebacker at the Woodberry Forest (Virginia) School.AdvertisementThis is placeholder textReceiving a preferred walk-on commitment this far ahead of National Signing Day is rare. But, according to Scout.com, Syracuse coach Mike Hart went to his high school to see two of his three-star teammates but immediately noticed Koch. Two days after Hart’s visit, Koch committed, per Scout.Koch becomes the fourth member of the 2017 class after Buffalo, New York native Isaiah McDuffie’s decommitment Wednesday. Koch is the third offensive player, joining Florida wide receiver Sharod Johnson and New Jersey quarterback Tommy DeVito.The Orange roster currently does not have a fullback on it. There are four true running backs listed: redshirt senior George Morris, sophomores Jordan Fredericks and Dontae Strickland and freshman Moe Neal.Track the entire Class of 2017 here.Here are his junior year highlights, via Hudl: Commentslast_img read more